MA52738A - Méthodes de traitement de l'arthrite psoriasique - Google Patents

Méthodes de traitement de l'arthrite psoriasique

Info

Publication number
MA52738A
MA52738A MA052738A MA52738A MA52738A MA 52738 A MA52738 A MA 52738A MA 052738 A MA052738 A MA 052738A MA 52738 A MA52738 A MA 52738A MA 52738 A MA52738 A MA 52738A
Authority
MA
Morocco
Prior art keywords
treatment methods
arthritis treatment
psoriasic arthritis
psoriasic
methods
Prior art date
Application number
MA052738A
Other languages
English (en)
Inventor
Pille Harrison
Luc Meuleners
Chantal Thérèse Tasset
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of MA52738A publication Critical patent/MA52738A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA052738A 2018-05-24 2019-05-23 Méthodes de traitement de l'arthrite psoriasique MA52738A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1808575.3A GB201808575D0 (en) 2018-05-24 2018-05-24 Methods for the treatment of psoriatic arthrits

Publications (1)

Publication Number Publication Date
MA52738A true MA52738A (fr) 2021-04-14

Family

ID=62812304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052738A MA52738A (fr) 2018-05-24 2019-05-23 Méthodes de traitement de l'arthrite psoriasique

Country Status (10)

Country Link
US (2) US12329758B2 (fr)
EP (1) EP3801548A1 (fr)
JP (3) JP2021524472A (fr)
KR (1) KR102955500B1 (fr)
CN (1) CN112203660B (fr)
AU (2) AU2019273664B2 (fr)
CA (1) CA3101386A1 (fr)
GB (1) GB201808575D0 (fr)
MA (1) MA52738A (fr)
WO (1) WO2019224283A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2021308574A1 (en) * 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
EP4287299A4 (fr) 2021-01-29 2025-01-01 LG Chem, Ltd. Électrode
EP4305062A1 (fr) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Méthode de traitement de patients souffrant de polyarthrite psoriasique ayant une réponse inadéquate à une thérapie par tnf avec un anticorps spécifique anti-il23

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (fr) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese et derives d'indolin-2-one
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004039816A1 (fr) 2002-10-29 2004-05-13 Shionogi & Co., Ltd. Cristal de sel acide inorganique d'un compose cephem
EP1601672B1 (fr) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (fr) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Derives de triazolopyridine comme agents antibacteriens
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (fr) 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
CA2691448A1 (fr) 2007-08-31 2009-03-05 Dominique Swinnen Composes de triazolopyridine et leur utilisation comme inhibiteurs de ask
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010186A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
US20110124692A1 (en) 2008-07-31 2011-05-26 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione compound and its manufacturing method
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP2013049632A (ja) 2011-08-30 2013-03-14 Kowa Co ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX368511B (es) * 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
KR20170134750A (ko) * 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
FI3595667T3 (fi) * 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta

Also Published As

Publication number Publication date
WO2019224283A1 (fr) 2019-11-28
US20260108530A1 (en) 2026-04-23
JP7751362B2 (ja) 2025-10-08
CA3101386A1 (fr) 2019-11-28
AU2025202777A1 (en) 2025-05-08
EP3801548A1 (fr) 2021-04-14
JP2021524472A (ja) 2021-09-13
JP2024069223A (ja) 2024-05-21
AU2019273664A1 (en) 2021-01-21
JP2025183397A (ja) 2025-12-16
US12329758B2 (en) 2025-06-17
US20210299135A1 (en) 2021-09-30
KR102955500B1 (ko) 2026-04-21
CN112203660B (zh) 2024-12-31
KR20210013168A (ko) 2021-02-03
AU2019273664B2 (en) 2025-01-23
GB201808575D0 (en) 2018-07-11
CN112203660A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3813806A4 (fr) Méthodes de traitement d'un dysfonctionnement mitochondrial
MA46954A (fr) Méthodes de traitement d'états inflammatoires
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3625971A4 (fr) Traitement d'audio spatial
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3781653A4 (fr) Traitement de biomasse à ph contrôlé
EP3775263A4 (fr) Compositions et méthodes de traitement de l'acné
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
EP3512524A4 (fr) Méthodes et compositions de traitement d'infections virales
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3773633A4 (fr) Méthodes de traitement de glioblastomes
IL268905B (en) Phage therapy
EP3383857A4 (fr) Composés et méthodes de traitement d'infections bactériennes
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3735209A4 (fr) Traitement de la progression de la myopie